WHITEHAWK THERAPEUTICS INC (WHWK) — insider trading
Health Care · NASDAQ
WHITEHAWK THERAPEUTICS INC (WHWK) has 59 reported SEC Form 4 insider transactions in our data, including 11 open-market sales among the most recent 59 (latest 2026-09-15).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | Lennon David James | Director, Officer (CHIEF EXECUTIVE OFFICER) | Grant / award / vesting (derivative) | 193,957 | — | $0 | Form 4/A |
| 2026-09-15 | Lennon David James | Director, Officer (CHIEF EXECUTIVE OFFICER) | Grant / award / vesting (derivative) | 193,957 | — | $0 | Form 4/A |
| 2026-09-15 | Giacobello Scott M. | Officer (CHIEF FINANCIAL OFFICER) | Grant / award / vesting (derivative) | 118,476 | — | $0 | Form 4/A |
| 2026-09-15 | Giacobello Scott M. | Officer (CHIEF FINANCIAL OFFICER) | Grant / award / vesting (derivative) | 118,476 | — | $0 | Form 4/A |
| 2026-09-15 | Dugan Margaret | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 81,250 | — | $0 | Form 4/A |
| 2026-09-15 | Dugan Margaret | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 81,250 | — | $0 | Form 4/A |
| 2026-09-15 | Dornan David | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 85,887 | — | $0 | Form 4/A |
| 2026-09-15 | Dornan David | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 85,887 | — | $0 | Form 4/A |
| 2026-09-15 | BALL BRYAN | Officer (See remarks) | Grant / award / vesting (derivative) | 91,633 | — | $0 | Form 4/A |
| 2026-09-15 | BALL BRYAN | Officer (See remarks) | Grant / award / vesting (derivative) | 91,633 | — | $0 | Form 4/A |
| 2026-09-15 | Lennon David James | Director, Officer (CHIEF EXECUTIVE OFFICER) | Grant / award / vesting (derivative) | 193,957 | — | $0 | Form 4 |
| 2026-09-15 | Lennon David James | Director, Officer (CHIEF EXECUTIVE OFFICER) | Grant / award / vesting (derivative) | 193,957 | — | $0 | Form 4 |
| 2026-09-15 | Giacobello Scott M. | Officer (CHIEF FINANCIAL OFFICER) | Grant / award / vesting (derivative) | 118,476 | — | $0 | Form 4 |
| 2026-09-15 | Giacobello Scott M. | Officer (CHIEF FINANCIAL OFFICER) | Grant / award / vesting (derivative) | 118,476 | — | $0 | Form 4 |
| 2026-09-15 | Dugan Margaret | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 81,250 | — | $0 | Form 4 |
| 2026-09-15 | Dugan Margaret | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 81,250 | — | $0 | Form 4 |
| 2026-09-15 | Dornan David | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 85,887 | — | $0 | Form 4 |
| 2026-09-15 | Dornan David | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 85,887 | — | $0 | Form 4 |
| 2026-09-15 | BALL BRYAN | Officer (See remarks) | Grant / award / vesting (derivative) | 91,633 | — | $0 | Form 4 |
| 2026-09-15 | BALL BRYAN | Officer (See remarks) | Grant / award / vesting (derivative) | 91,633 | — | $0 | Form 4 |
| 2026-09-09 | Iyengar Vijay K | Director | Grant / award / vesting (derivative) | 76,080 | — | $0 | Form 4 |
| 2026-06-12 | Dalal Anupam | Director | Grant / award / vesting (derivative) | 38,040 | — | $0 | Form 4 |
| 2026-06-12 | Aghazadeh Behzad; Avoro Capital Advisors LLC; Avoro Ventures LLC | Director, 10% owner, Other | Grant / award / vesting (derivative) | 38,040 | — | $0 | Form 4 |
| 2026-06-12 | Castelein Caley | Director | Grant / award / vesting (derivative) | 38,040 | — | $0 | Form 4 |
| 2026-06-12 | Desai Neil | Director | Grant / award / vesting (derivative) | 38,040 | — | $0 | Form 4 |
| 2026-06-12 | Hirmand Mohammad | Director | Grant / award / vesting (derivative) | 38,040 | — | $0 | Form 4 |
| 2026-06-12 | Maroun Richard E | Director | Grant / award / vesting (derivative) | 38,040 | — | $0 | Form 4 |
| 2026-06-12 | Reeve Emma | Director | Grant / award / vesting (derivative) | 38,040 | — | $0 | Form 4 |
| 2026-06-12 | Zhao Baiteng | Director | Grant / award / vesting (derivative) | 38,040 | — | $0 | Form 4 |
| 2026-05-14 | Dalal Anupam | Director | Grant / award / vesting | 1,275,510 | $3.92 | $5.00M | Form 4 |
| 2026-05-14 | Castelein Caley | Director | Grant / award / vesting (derivative) | 2,072,756 | $8,124,996.24 | $16841.13B | Form 4 |
| 2026-05-14 | Castelein Caley | Director | Grant / award / vesting | 255,102 | $3.92 | $1000.0K | Form 4 |
| 2026-05-14 | Lennon David James | Director, Officer (CHIEF EXECUTIVE OFFICER) | Grant / award / vesting | 51,021 | $3.92 | $200.0K | Form 4 |
| 2026-05-14 | Giacobello Scott M. | Officer (CHIEF FINANCIAL OFFICER) | Grant / award / vesting | 38,265 | $3.92 | $150.0K | Form 4 |
| 2026-05-14 | BALL BRYAN | Officer (See remarks) | Grant / award / vesting | 51,020 | $3.92 | $200.0K | Form 4 |
| 2026-05-14 | Dugan Margaret | Officer (Chief Medical Officer) | Grant / award / vesting | 19,132 | $3.92 | $75.0K | Form 4 |
| 2026-05-12 | Avoro Capital Advisors LLC; Aghazadeh Behzad; Avoro Ventures LLC | Director, 10% owner, Other | Grant / award / vesting (derivative) | 6,377,714 | $3.92 | $25.00M | Form 4 |
| 2026-04-16 | Giacobello Scott M. | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 141,600 | $4.13 | $584.8K | Form 4 |
| 2026-04-15 | Giacobello Scott M. | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 77,000 | $3.86 | $297.2K | Form 4 |
| 2026-04-14 | BALL BRYAN | Officer (See remarks) | Open-market sale | 92,460 | $3.64 | $336.6K | Form 4 |
| 2026-04-13 | BALL BRYAN | Officer (See remarks) | Open-market sale | 26,389 | $3.46 | $91.3K | Form 4 |
| 2026-04-10 | BALL BRYAN | Officer (See remarks) | Open-market sale | 6,596 | $3.43 | $22.6K | Form 4 |
| 2026-04-09 | BALL BRYAN | Officer (See remarks) | Open-market sale | 50,000 | $3.57 | $178.5K | Form 4 |
| 2026-04-09 | Lennon David James | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 14,500 | $3.38 | $49.0K | Form 4 |
| 2026-04-08 | Lennon David James | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 63,945 | $3.40 | $217.4K | Form 4 |
| 2026-04-07 | Lennon David James | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 94,087 | $3.43 | $322.7K | Form 4 |
| 2026-04-06 | Lennon David James | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 102,395 | $3.51 | $359.4K | Form 4 |
| 2026-04-02 | Lennon David James | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 26,858 | $3.48 | $93.5K | Form 4 |
| 2026-04-01 | Lennon David James | Director, Officer (CHIEF EXECUTIVE OFFICER) | Grant / award / vesting (derivative) | 831,148 | — | $0 | Form 4 |
| 2026-04-01 | Lennon David James | Director, Officer (CHIEF EXECUTIVE OFFICER) | Option exercise / conversion (derivative) | 775,828 | — | $0 | Form 4 |
| 2026-04-01 | Lennon David James | Director, Officer (CHIEF EXECUTIVE OFFICER) | Option exercise / conversion | 775,828 | — | — | Form 4 |
| 2026-04-01 | Giacobello Scott M. | Officer (CHIEF FINANCIAL OFFICER) | Grant / award / vesting (derivative) | 300,677 | — | $0 | Form 4 |
| 2026-04-01 | Giacobello Scott M. | Officer (CHIEF FINANCIAL OFFICER) | Option exercise / conversion (derivative) | 473,902 | — | $0 | Form 4 |
| 2026-04-01 | Giacobello Scott M. | Officer (CHIEF FINANCIAL OFFICER) | Option exercise / conversion | 473,902 | — | — | Form 4 |
| 2026-04-01 | BALL BRYAN | Officer (See remarks) | Grant / award / vesting (derivative) | 250,058 | — | $0 | Form 4 |
| 2026-04-01 | BALL BRYAN | Officer (See remarks) | Option exercise / conversion (derivative) | 366,532 | — | $0 | Form 4 |
| 2026-04-01 | BALL BRYAN | Officer (See remarks) | Option exercise / conversion | 366,532 | — | — | Form 4 |
| 2026-04-01 | Dugan Margaret | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 283,157 | — | $0 | Form 4 |
| 2026-04-01 | Dornan David | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 282,340 | — | $0 | Form 4 |
Ask the chat about WHWK's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: WHITEHAWK THERAPEUTICS INC (WHWK).
Last updated 2026-09-15 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.